| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/27/2001 | CA2317064A1 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 02/27/2001 | CA2316662A1 Use of crf antagonists and related compositions |
| 02/27/2001 | CA2194370C Attenuation of wound healing processes |
| 02/27/2001 | CA2189526C Perfluoroalkyl ketone inhibitors of elastase and processes for making the same |
| 02/27/2001 | CA2124206C Indole derivatives |
| 02/27/2001 | CA2012267C Interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| 02/22/2001 | WO2001013108A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | WO2001013031A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | WO2001012823A2 Macular degeneration diagnostics and therapeutics |
| 02/22/2001 | WO2001012818A1 Neutral cerebral-sphingomyelinase |
| 02/22/2001 | WO2001012812A2 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | WO2001012805A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012787A2 Chimeric dna/rna ribozymes containing propanediol |
| 02/22/2001 | WO2001012785A1 Ex vivo generation of functional osteoclasts from bone marrow in a three-dimensional bioreactor |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012665A2 Helical cytokine zalpha48 |
| 02/22/2001 | WO2001012632A2 Phenanthroline-7-one derivatives and their therapeutic uses |
| 02/22/2001 | WO2001012629A1 Azaindoles having serotonin receptor affinity |
| 02/22/2001 | WO2001012628A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | WO2001012622A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012612A1 Benzoic acid derivatives for the treatment of diabetes mellitus |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012603A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | WO2001012602A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012591A1 Novel naphthylsulfonic acids and related compounds as glucose uptake agonists |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012264A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012227A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/22/2001 | WO2001012226A1 Angiogenesis inhibitors comprising as the active ingredient compound having chymase inhibitory effect |
| 02/22/2001 | WO2001012225A1 Water channel opener compositions and medicinal compositions for ophthalmic use |
| 02/22/2001 | WO2001012214A2 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 02/22/2001 | WO2001012212A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | WO2001012208A1 Use of ginkgo extract |
| 02/22/2001 | WO2001012197A1 Pyridomorphinans, thienomoprhinans and use thereof |
| 02/22/2001 | WO2001012195A2 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012187A2 Benzoic acid derivatives and their use as ppar receptor agonists |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012184A1 Neurotherapeutic composition and method |
| 02/22/2001 | WO2001012182A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | WO2001012181A1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 02/22/2001 | WO2001012180A2 Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce |
| 02/22/2001 | WO2001012171A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001012127A2 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 02/22/2001 | WO2001011967A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000077246A3 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 02/22/2001 | WO2000074677A3 Improved pharmaceutical formulations |
| 02/22/2001 | WO2000073330A3 Method and compositions relating to insulin resistance disorders |
| 02/22/2001 | WO2000072742A3 Methods and materials for generating sh3 domains with tailored binding properties |
| 02/22/2001 | WO2000072008A3 Identification of novel mechanisms of drug resistance |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000064936A3 PEPTIDE HOMODIMERS AND PEPTIDE HETERODIMERS, DERIVED FROM INTERFERON α2 |
| 02/22/2001 | WO2000055633A3 Methods of screening for colorectal cancer modulators |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000049138A3 Pluripotential cells derived from embryonal teratocarcinoma cells and the nucleus of stomatic cells |
| 02/22/2001 | WO2000040614A3 Characterization of the soc/crac calcium channel protein family |
| 02/22/2001 | WO2000039716A3 Arylpropenylimidazoles as farnesyl-protein transferase inhibitors |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | WO1999063992A8 Novel calcium channel drugs and uses |
| 02/22/2001 | WO1999058680A3 Method for diagnosis and treatment of haemophilia a patients with an inhibitor |
| 02/22/2001 | WO1999056771A3 Methods of raising animals for meat production |
| 02/22/2001 | WO1999050275A3 Macrolide lhrh antagonists |
| 02/22/2001 | WO1999046279A3 INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 02/22/2001 | DE19939756A1 New 1-(1-ethyl-piperidin-4-yl)-1-(phenyl or heterocyclyl)-alkanol derivatives, are 5-HT(2A) receptor antagonists useful e.g. for treating schizophrenia, depression, memory disorders or eating disorders |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | DE19938823A1 Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2383154A1 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382251A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2381976A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381794A1 Helical cytokine zalpha48 |
| 02/22/2001 | CA2381780A1 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | CA2381700A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2381352A1 Phenanthroline-7-one derivatives and their therapeutic uses |
| 02/22/2001 | CA2381090A1 Benzoic acid derivatives for the treatment of diabetes mellitus |
| 02/22/2001 | CA2380979A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | CA2380820A1 Neurotherapeutic clavulanate composition and method |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380814A1 Pyridomorphinans, thienomorphinans and use thereof |